Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin
The primary objective is to investigate the optimal daily dose and dose regimen of YM150 in subjects with NVAF, primarily based on safety and tolerability data.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
This is a short study, performed in different countries, to investigate how well one dose of mirabegron in tablet form is taken up, how long it stays in the body and how well it will be tolerated in children/adolescents aged 5 to less than 18 years with symptoms of neurogenic detrusor overactivity or overactive bladder
To evaluate the pharmacokinetics of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Astellas Pharma
MAJ Il y a 4 ans
Étude CL-0301 : étude de phase 3 randomisée évaluant l'efficacité, la sécurité et la tolérance du zolbetuximab associé à une chimiothérapie de type mFOLFOX6 par rapport à un placebo associé à une chimiothérapie de type mFOLFOX6 dans le traitement du cancer de l'estomac et du cancer de la jonction gastro-oesophagienne.
Le cancer de l’estomac est une pathologie fréquente, quatrième place en termes d’incidence des cancers avec une augmentation des cancers de la jonction oesogastrique. Son prognostique reste médiocre. ...
Pays
France
Organes
Cardia (jonction gastro-œsophagienne)
,
Estomac
Spécialités
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma GmbH
MAJ Il y a 4 ans
A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLANTATION
Primary objective of this study is to compare the two therapy regimens (Arm 1: tacrolimus + sirolimus + corticosteroids, Arm 2: tacrolimus + MMF + corticosteroids)with regard to renal function by usin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
This clinical study investigates the effect of fidaxomicin in comparison to vancomycin in adult patients with an infection of Clostridium difficile, and are using medicinal products that suppress the immune system
The primary objective of the study is to demonstrate superiority of fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V. (APEB)
MAJ Il y a 4 ans
A study to evaluate the effect on pain relief and safety of a new treatment (ASP8477) with a mock treatment (placebo) in subjects with Peripheral Neuropathic Pain
To assess analgesic efficacy of ASP8477 relative to placebo in subjects with peripheral neuropathic pain as determined by the change in the average daily pain intensity in responders.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia
To assess the effect of Tamsulosin OCAS 0.4 mg o.d. compared to placebo on improvement of nocturnal voiding frequency, in subjects with LUTS associated with BPH over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
Roxadustat in the treatment of anemia in end stage renal disease patients on stable dialysis
Evaluate the efficacy of roxadustat compared to epoetin alfa and darbepoetin alfa in the maintenance treatment of anemia in End Stage Renal Disease (ESRD) subjects on stable dialysis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS IN CHILDREN AFTER KIDNEY TRANSPLANTATION
The primary objective of this study is to investigate the impact of early corticosteroid withdrawal in paediatric renal transplant patients on growth expressed as change in height SDS from baseline to...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis
To evaluate the efficacy and safety of YM672 administered orally in the treatment of painful bladder syndrome (PBS)/interstitial cystitis (IC). The primary efficacy endpoint is success, defined as ‘Mo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant